Wuxi apptec announced the acquisition of pharmapace in the United States to expand the statistical analysis service capacity of clinical research data

May 6, 2019 / AP / -- Wuxi apptec today announced its successful acquisition of pharmapace, an American clinical research service The company provides high-quality data statistical analysis services for all stages of clinical trials, registration application and post IPO support Upon completion of the acquisition, pharmapace will become a wholly-owned subsidiary of Kant Hongyi, a clinical cro company of Wuxi Pharmaceutical Co., Ltd., and will continue to focus on expanding its core data statistical analysis service capabilities In the future, pharmapace will integrate with related clinical research services of Kant Hongyi Founded in 2013, pharmapace is located in San Diego, California, USA It provides a full range of services including clinical and statistical planning, data management, biostatistics, clinical data integration and medical writing for customers in North America, Europe and Asia Through this acquisition and the integration of the professional teams of both parties, Kant Hongyi will further expand its clinical research data statistical analysis service capabilities in the United States and Europe, and provide professional biostatistics services for global customers, as well as more efficient and cost-effective all-weather one-stop clinical data statistical analysis services After the acquisition of pharmapace, Kant Hongyi will have a service team of more than 850 people in China and the United States Together with the company's strategic partners in Europe and the Asia Pacific region, they will provide comprehensive clinical development services and functional service outsourcing (FSP) to global customers With the announcement of China National Drug Administration (nmpa) accepting overseas clinical trial data, innovators from all over the world have an unprecedented new opportunity to promote and integrate regional and global clinical research process through Kant Hongyi's platform "We are very happy to be a member of Wuxi apptec As a leading global capability and technology platform company, Wuxi apptec has outstanding brand influence and industry successful experience Wuxi apptec adheres to the concept of "customer first" and we share the same aspiration We are also moved by Wuxi apptec's feelings of "helping anyone and any company realize their R & D dream and benefit the vast number of patients" Through this M & A, we will provide customers with a global integrated solution from pre clinical development, clinical research to registration and application by virtue of the platform capacity and scale of Wuxi apptec " Dr Shen Zaiqian, President and CEO of pharmapace, said "Pharmapace is very welcome to join the pharmapace family Under the leadership of Dr Shen and his management team, pharmapace has grown into a highly acclaimed clinical research service company in the United States " Hu Zhengguo, CO CEO of Wuxi apptec, said, "this acquisition further improves the all-round data statistical analysis service ability of Kant Hongyi and lays a solid foundation for us to create a global integrated clinical research service platform In the future, we will work hand in hand with pharmapace to help partners shorten the process of new drug listing and realize the great dream of "let the world have no hard drugs and diseases to cure" as soon as possible " As a leading open capability and technology platform company in the world, Wuxi apptec provides all-round integrated laboratory R & D and production services from drug discovery, development to marketization in the fields of global pharmaceutical and medical devices With the purpose of taking research as the first task and customer as the center, Wuxi apptec helps global customers shorten the R & D cycle of drugs and medical devices and reduce the R & D cost through a cost-effective and efficient service platform The platform includes small molecule drug R & D and production, cell therapy and gene therapy R & D and production, medical device testing, etc it is carrying thousands of R & D and innovation projects from more than 3500 innovation partners from more than 30 countries around the world, and is committed to bringing the latest and best medicine and health products to patients around the world, so as to realize "no hard medicine, no hard disease to treat" ”Dream of.